Potential Predictors and Response Quality after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

II Kostroma1, ZhYu Sidorova1, NYu Semenova1, AA Zhernyakova1, RR Sabitova1, SP Svitina1, EI Stepchenkova2,3, SS Bessmeltsev1, AV Chechetkin1, SV Gritsaev1

1 Russian Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024

2 Saint Petersburg State University, 7/9 Universitetskaya emb., Saint Petersburg, Russian Federation, 199034

3 NI Vavilov Institute of General Genetics, Saint Petersburg branch, 7/9 Universitetskaya emb., Saint Petersburg, Russian Federation, 199034

For correspondence: Ivan Ivanovich Kostroma, MD, PhD, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024; Tel.: +7(921)784-82-82; e-mail: obex@rambler.ru

For citation: Kostroma II, Sidorova ZhYu, Semenova NYu, et al. Potential Predictors and Response Quality after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Clinical oncohematology. 2021;14(3):333–9. (In Russ).

DOI: 10.21320/2500-2139-2021-14-3-333-339


Aim. To assess the rate of cases without antitumor response quality improvement after high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma (MM). To assess the rate of allelic variants of IL1B, IL6, IL10, TNF genes and the status of hematopoietic niche cells as potential predictors of auto-HSCT efficacy.

Materials & Methods. A retrospective analysis was based on the data of 84 MM patients who received 112 auto-HSCTs, including 84 first and 28 repeated courses. Response variants were estimated according to IWG criteria. Molecular profiling of IL1B, IL6, IL10, and TNF genes was performed using polymerase chain reaction (PCR) with subsequent analysis of restriction fragment length polymorphism of PCR products. To analyze the status of hematopoietic niche cells histological, immunohistochemical, and morphometric methods were applied.

Results. The first auto-HSCT yielded response quality improvement in 29 (54.7 %) out of 84 patients. The rate of complete response was significantly higher in patients who showed very good partial response before HDCT with auto-HSCT, than in patients with partial response (PR), i.e., 57.9 % and 18.2 %, respectively (р = 0.005). No differences were identified in the groups of patients with other clinical and hematological parameters. After the second auto-HSCT in 4 out of 6 patients with PR the response variant did not change. A significant decrease of MM activity was associated with IL6 (–174С) mutant allele carrier status of 81.3 % vs. 41.6 % in the group with the unchanged response variant (р = 0.05). Response quality improvement was also related to a large number of cells on the endosteum in histological specimens of bone marrow (р = 0.038).

Conclusion. The carrier status of IL6 (–174С) pathologic allele as well as the number of cells on the endosteum in histological specimens of bone marrow can be regarded as predictors of response quality improvement or lack thereof in MM patients after auto-HSCT.

Keywords: multiple myeloma, autologous hematopoietic stem cell transplantation, IL6 gene, hematopoietic niche.

Received: January 29, 2021

Accepted: May 30, 2021

Read in PDF

Статистика Plumx английский


  1. Legarda MA, Cejalvo MJ, de la Rubia J. Recent advances in the treatment of patients with multiple myeloma. Cancers (Basel). 2020;12(12):3576. doi: 10.3390/cancers12123576.
  2. Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. 2020;105(10):2358–67. doi: 10.3324/haematol.2020.247015.
  3. Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(25):5988–99. doi: 10.1182/bloodadvances.2020002827.
  4. Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома: руководство для врачей. М.: СИМК, 2016. 512 с.
    [Bessmeltsev SS, Abdulkadyrov KM. Mnozhestvennaya mieloma: rukovodstvo dlya vrachei. (Multiple myeloma: manual for physicians.) Moscow: SIMK Publ.; 2016. 512 p. (In Russ)]
  5. Менделеева Л.П., Вотякова О.М., Покровская О.С. и др. Национальные клинические рекомендации по диагностике и лечению множественной миеломы. Гематология и трансфузиология. 2016;61(1, прил. 2):1–24. doi: 10.18821/0234-5730-2016-61-1-S2-1-24.
    [Mendeleeva LP, Votyakova OM, Pokrovskaya OS, et al. National clinical guidelines on diagnosis and treatment of multiple myeloma. Gematologiya i transfuziologiya. 2016;61(1, Suppl 2):1–24. doi: 10.18821/0234-5730-2016-61-1-S2-1-24. (In Russ)]
  6. Attal M, Harousseau J-L, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–502. doi: 10.1056/NEJMoa032290.
  7. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25(17):2434–41. doi: 10.1200/JCO.2006.10.2509.
  8. Mai TR, Benner F, Bertsch U, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol. 2016;173(5):731–41. doi: 10.1111/bjh.13994.
  9. Blocka J, Hielscher T, Goldschmidt H, Hillengass J. Response improvement rather than response status after first autologous stem cell transplantation is a significant prognostic factor for survival benefit from tandem compared with single transplantation in multiple myeloma patients. Biol Blood Marrow Transplant. 2020;26(7):1280–7. doi: 10.1016/j.bbmt.2020.03.006.
  10. Грицаев С.В., Кострома И.И., Жернякова А.А. и др. Опыт применения режима кондиционирования Thio/Mel перед трансплантацией аутологичных гемопоэтических стволовых клеток при множественной миеломе. Клиническая онкогематология. 2019;12(3):282–8. doi: 10.21320/2500-2139-2019-12-3-282-288.
    [Gritsaev SV, Kostroma II, Zhernyakova AA, et al. Experience with the Use of Thio/Mel Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Clinical oncohematology. 2019;12(3):282–8. doi: 10.21320/2500-2139-2019-12-3-282-288. (In Russ)]
  11. Кострома И.И., Жернякова А.А., Запреева И.М. и др. Опыт включения карфилзомиба в состав режима кондиционирования при выполнении аутологичной трансплантации гемопоэтических стволовых клеток больным множественной миеломой. Гематология и трансфузиология. 2020;65(1, прил. 1):155.
    [Kostroma II, Zhernyakova AA, Zapreeva IM, et al. Experience with the inclusion of carfilzomib into the conditioning regimen when performing autologous stem cell transplantation in patients with multiple myeloma. Gematologiya i transfuziologiya. 2020;65(1, Suppl 1):155. (In Russ)]
  12. Gagelmann N, Kroger N. The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review. Ann Hematol. 2020;100(2):405–19. doi: 10.1007/s00277-020-04316-8.
  13. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73. doi: 10.1038/sj.leu.2404284.
  14. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–5. doi: 10.1182/blood-2010-10-299487.
  15. Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529–34. doi: 10.1182/blood-2011-01-332320.
  16. Brioli A, vom Hofe F, Rucci P, et al. Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients. Bone Marrow Transplant. 2020. Published online ahead of print. doi: 10.1038/s41409-020-01170-0.
  17. Katragadda L, McCullough LM, Dai Y, et al. Effect of melphalan 140 mg/m2 vs 200 mg/m2 on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience. Clin Transplant. 2016;30(8):894–900. doi: 10.1111/ctr.12762.
  18. Ghilardi G, Pabst T, Jeker B, et al. Melphalan dose in myeloma patients ≥ 65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone Marrow Transplant. 2019;54(7):1029–37. doi: 10.1038/s41409-018-0379-y.
  19. Кострома И.И., Жернякова А.А., Запреева И.М. и др. Ретроспективный анализ выживаемости больных множественной миеломой после трансплантации аутологичных гемопоэтических стволовых клеток. Клиническая онкогематология. 2021;14(1):73–9. doi: 10.21320/2500-2139-2021-14-1-73-79.
    [Kostroma II, Zhernyakova AA, Zapreeva IM, et al. Retrospective survival analysis of multiple myeloma patients after autologous hematopoietic stem cell transplantation. Clinical oncohematology. 2021;14(1):73–9. doi: 10.21320/2500-2139-2021-14-1-73-79. (In Russ)]
  20. Bygrave C, Pawlyn C, Davies F, et al. Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. Br J Haematol. 2020. Published online ahead of print. doi: 10.1111/bjh.16793.
  21. Dhakal B, D’Souza A, Callander N, et al. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol. 2020;191(3):442–52. doi: 10.1111/bjh.16987.
  22. Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125(20):3059–68. doi: 10.1182/blood-2014-11-568907.
  23. Lee B-H, Park Y, Kim JH, et al. PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model. Sci Rep. 2020;10(1):12641. doi: 10.1038/s41598-020-69616-5.
  24. Soliman AM, Lin TS, Mahakkanukrauh P, Das S. Role of microRNAs in diagnosis, prognosis, and management of multiple myeloma. Int J Mol Sci. 2020;21(20):7539. doi: 10.3390/ijms21207539.
  25. Duch CR, Figueiredo MS, Ribas C, et al. Analysis of polymorphism at site -174 G/C of interleukin-6 promoter region in multiple myeloma. Braz J Med Biol Res. 2007;40(2):265–7. doi: 10.1590/s0100-879х2007000200014.
  26. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226(1):205–18. doi: 10.1111/j.1600-065X.2008.00706.x.
  27. Типтева Т.А., Чумакова О.С., Бакланова Т.Н. и др. Однонуклеотидный полиморфизм С(-592)А гена интерлейкина-10 ассоциирован с аортальным стенозом. Кремлевская медицина. Клинический вестник. 2017;1:24–31.
    [Tipteva TA, Chumakova OS, Baklanova TN, et al. Single-nucleotide polymorphism С(-592)А of interleukin-10 gene is associated with aortic stenosis. Kremlevskaya meditsina. Klinicheskii vestnik. 2017;1:24–31. (In Russ)]
  28. Ругаль В.И., Бессмельцев С.С., Семенова Н.Ю. и др. Характеристика микроокружения костного мозга при множественной миеломе до и после терапии. Сибирский научный медицинский журнал. 2019;39(1):112–8. doi: 10.15372/SSMJ
    [Rugal VI, Bessmeltsev SS, Semenova NYu, et al. Characteristics of bone marrow microenvironment in multiple myeloma before and treatment. Sibirskii nauchnyi meditsinskii zhurnal. 2019;39(1):112–8. doi: 10.15372/SSстMJ20190116. (In Russ)]
  29. Ellis SL, Grassinger J, Jones A, et al. The relationship between bone, hemopoietic stem cells, and vasculature. Blood. 2011;118(6):1516–24. doi: 10.1182/blood-2010-08-303800.
  30. Покровская О.С., Менделеева Л.П., Капланская И.Б. и др. Ангиогенез в костном мозге больных множественной миеломой на различных этапах высокодозной химиотерапии. Клиническая онкогематология. 2010;3(4):347–53.
    [Pokrovskaya OS, Mendeleeva LP, Kaplanskaya IB, et al. Bone marrow angiogenesis in patients with multiple myeloma at different stages of high-dose therapy. Klinicheskaya onkogematologiya. 2010;3(4):347–53. (In Russ)]